Bio-Rad introduces Unity Next Peer QC
December 2022—Bio-Rad Laboratories has launched Unity Next Peer QC, a quality control peer comparison software that provides access to peer reporting and comprehensive quality control data.
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
CAP TODAY
Roche introduces Cobas 5800 to expand access to PCR testing in the U.S.
December 2022—Roche announced plans for the U.S. launch of the Cobas 5800 system, a compact, fully-automated molecular instrument that aims to offer a flexible PCR testing solution to help clinicians diagnose infectious diseases.
Verichem reference materials for lactate assays
December 2022—Verichem Laboratories announced the availability of a six-level, protein-based kit designed for the calibration or calibration verification of lactate assays on automated clinical systems. The liquid-stable, ready-to-use product contains concentration levels of lactate ranging from 3.2 mg/dL to 160 mg/dL. The format is free of glycols, surfactants, azides, and other interfering substances. Shelf life is 18 months from the manufacturing date.
Primera slide, cassette printers
December 2022—Primera Technology showcased its Signature EVO slide and cassette printers at the National Society for Histotechnology convention.
OGT launches NGS myeloid panel, library prep workflow
December 2022—OGT launched its SureSeq Myeloid Plus panel designed to detect a range of aberrations, including single nucleotide variations, insertions/deletions, internal tandem duplications, and partial tandem duplications in 49 genes implicated in myeloid disorders such as acute myeloid leukemia, myeloproliferative neoplasms, and myelodysplastic syndrome.
Bio-Rad introduces InteliQ QC for Beckman AU series analyzers
November 2022—Bio-Rad Laboratories has collaborated with Beckman Coulter to offer InteliQ load-and-go quality controls for use on Beckman Coulter DxC AU and AU series clinical chemistry analyzers.
Siemens launches Innovance VWF Ac assay
November 2022—Siemens Healthineers announced that its Innovance VWF Ac assay is available to U.S. laboratories for use on the company’s BCS XP system and on Sysmex CS-2500 and CS-5100 hemostasis analyzers.
Traceable updates four products
November 2022—Traceable announced it has updated four of its products—a refrigerator/freezer digital thermometer with probe, a thermohygrometer with clock, a three-channel timer with alarm, and a four-channel timer with clock—to be more user friendly, economical, and higher performing. The updates are based on feedback that the company gathered from customer focus groups and industry conversations to learn how clinics, laboratories, academic institutions, logistics companies, and other organizations use its products.
Thermo Fisher Scientific buys Binding Site
November 2022—Thermo Fisher Scientific announced it has entered into a definitive agreement to acquire the Binding Site Group from a shareholder group led by European private equity firm Nordic Capital. The all-cash transaction is valued at approximately $2.6 billion at current exchange rates, Thermo Fisher reported in a press release.
FDA clears COVID-19 PCR test on Cobas 6800/8800 systems
November 2022—Roche announced that the FDA has granted 510(k) clearance for the Cobas SARS-CoV-2 Qualitative PCR test for use on the automated Cobas 6800 and Cobas 8800 systems. It is a real-time RT-PCR test intended for the qualitative detection of nucleic acids from SARS-CoV-2 in nasal and nasopharyngeal swab specimens collected from symptomatic patients who are suspected of having COVID-19 by their health care provider. The single-well, dual-target assay includes specific detection of SARS-CoV-2 and pan-sarbecovirus detection for the sarbecovirus subgenus that includes SARS-CoV-2.